Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

The Maravi Post ...

Moderna stock rises as Q3 revenue beats estimates at $1.83 billion, driven by strong U.S. COVID-19 vaccine sales. EPS of $0.03 exceeds expectations.

A new study by the World Health Organization (WHO) lists 17 bacteria, viruses and parasites that regularly cause disease as top priorities for new vaccine development. UN Health News ...